Drug Company Cries Foul Over Clams Of Taxotere’s Superiority To Taxol
In Brief: Harold Moses Directs Vanderbilt Cancer Center; Carl Fretts, NIH contracts Director, To Retire
Interactive R01 Scores Vary widely, Result Of separate Review
Fisher, Bonadonna, Croce, Hanafusa Win GAM Cancer Prizes
ASCO Honors Holland, Koop, Monaco With Special Awards
ONS To Fund 21 Grants In ’94 Deadline Dec. 1
Prevention & Control Study Section Needed: Letter to the Editor
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
